Compare TG Therapeutics Inc (TGTX) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? TG Therapeutics Inc trades at $55 (market cap $8.16B), while State Street SPDR S&P Homebuilders ETF trades at $94.83 (market cap $1.49B). The key difference: TG Therapeutics Inc is far larger — about 5.5× State Street SPDR S&P Homebuilders ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, State Street SPDR S&P Homebuilders ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and State Street SPDR S&P Homebuilders ETF for 33 Days on average.
| TGTX | XHB | |
|---|---|---|
Market Cap | $8.16B | $1.49B |
Volume | 1,735,121 | 2,445,587 |
Sector | Health | Broad Market / Factor |
52-Week High | $59.06 | $121.36 |
52-Week Low | $26.94 | $94.86 |
Typical Hold Time | 16 Days | 33 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
XHB (SPDR S&P Homebuilders ETF) trades at $94.77, down 0.13% with a bearish technical outlook from moving averages. The ETF tracks homebuilder stocks facing headwinds from rising mortgage rates near 7%, though recent news highlights potential buying opportunities amid sector undervaluation. Technical indicators show neutral oscillators but bearish momentum with support at $94 and resistance at $96.
The housing market faces mixed signals with rising rates pressuring affordability, but legislative support and institutional interest suggest long-term potential. Key risks include mortgage rate volatility and economic sensitivity, while analyst coverage emphasizes sector recovery prospects. Investment appeal hinges on housing market stabilization and policy impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
